
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
Bristol Myers Squibb (BMY) stock skidded late Monday — tugging shares of rival Cytokinetics (CYTK) lower — after Bristol's drug, Camzyos, failed in a final-phase study of patients with a devastating heart disease. The company tested Camzyos in patients …